Candesartan in the Prevention of Relapsing Atrial Fibrillation

• Status: Completed
• Trial end date: 2005-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the hypothesis that treatment with the angiotensin II type 1 receptor antagonist candesartan may reduce the recurrence rate of atrial fibrillation after electrical cardioversion.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asker & Baerum Hospital
• Collaborators: AstraZeneca; Helse Ost; Ullevaal University Hospital
• Treatments: Candesartan; Candesartan cilexetil

Criteria

Inclusion Criteria:

• Patients with atrial fibrillation, diagnosed electrocardiographically, of more than 48 hours duration in whom direct current (DC) cardioversion is planned.

Exclusion Criteria:

• Patients with a history of known hypersensitivity or contraindication to any angiotensin II receptor blocker or any angiotensin-converting enzyme (ACE) inhibitor.

• Patients currently receiving an ACE inhibitor or angiotensin II antagonist because of heart failure or other strong indication.

• Patients currently receiving any antiarrhythmic medication including sotalol. Other beta-blockers will not be regarded as specific antiarrhythmic agents.

• Significant renal artery stenosis and any medical condition in which administration of a vasodilator is contraindicated; serum creatinine > 225 micromol/L; or serum potassium > 5.5 mmol/L; or serum sodium < 128 mmol/L.

• Patients with severe hepatic dysfunction.

• Life-limiting disease or substance abuse which may affect participation.

• Patients unwilling to participate.

• Patients who have previously undergone DC cardioversion for atrial fibrillation within the last month.

• Thyrotoxicosis.

• Patients with a systolic blood pressure of < 100 mm Hg.

• Hypertensive patients requiring intensified treatment prior to DC cardioversion.

• Pregnancy or lactation.